Compare Amphastar Pharmaceuticals Inc (AMPH) vs Rivian Automotive, Inc. (RIVN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Rivian (RIVN) trades at $17.48, down 3.69% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company continues to post revenue growth, reaching $5.39 billion in 2025, but remains unprofitable with a net loss of $3.65 billion. Recent news highlights a $1.74 billion stock offering for factory expansion, causing dilution concerns but also reflecting growth ambitions.

The outlook hinges on Rivian's ability to scale production and achieve profitability, supported by analyst consensus targets of $20. Key risks include persistent cash burn, competitive pressures, and execution challenges. The stock presents a high-risk, high-reward opportunity for investors betting on the EV maker's long-term growth trajectory.